Lancet sub-journal: Testosterone or can treat type 2 diabetes in men?!

Exogenetic testosterone therapy (TTh) is currently the most widely used treatment in adult patients with glandular decompression disorders because it increases serum testosterone (T) levels.
, however, studies have shown that TTh may affect cardiovascular (CV) risk factors in patients with AOH, and that low endo-T levels are associated with increased CV risk and mortality.
to this end, in January 2020, the American Medical Association (ACP) issued guidelines for the treatment of testosterone with low age-related low testosterone levels in adult males, and the ACP panel of experts recommended guidance on age-related low testosterone levels in adult males based on the latest evidence.
type 2 diabetes (T2DM), formerly known as adult type 2 diabetes, mostly after the age of 35 to 40, accounting for more than 90% of diabetics.
T2DM patients' ability to produce insulin is not completely lost, some patients even produce too much insulin in the body, but the effect of insulin is poor, so the patient's body insulin is a relative lack, can be stimulated by certain oral drugs in the body insulin secretion.
Diabetes Care. 2019 Jun; 42(6):1104-1111. doi: 10.2337/dc18-2388. Where the prediabetes stage provides a window of intervention to prevent the development of T2D.
, men with T2DM and prediabetes usually have lower testosterone levels.
, overweight or obese men often have low serum testosterone levels, which are also associated with an increased risk of T2DM.
because testosterone improves T2DM's blood sugar control, researchers are concerned about whether TTh can prevent prediabetes with hypoglycertic glands from progressing to the T2DM stage.
, published online March 12, 2019 in the journal Diabetes Care, showed that TTh completely prevented men with hypothyroidism and prediabetes from developing to T2DM.
, can TTh prevent or reverse T2DM? To do this, researchers from Australia have conducted a study called T4DM (Testosterone Prevents Diabetes).
results were published in The Lancet Diabetes Endocrinology journal The Lancet Diabetes Endocrinology.
T4DM was a randomized, double-blind, placebo-controlled, two-year Phase 3b trial completed at six level 3 medical centres in Australia.
included more than 1,000 people aged 50-74 years, 95cm or more waist circumference, serum testosterone concentration 14-0nmol/L or less, but no pathological gland function reduction, impaired glucose tolerance (oral glucose resistance) A man with a volume test of 2-h glucose 7-8-11-0mmol/L) or a newly diagnosed T2DM (provided OGTT 2-h glucose ≤15-0mmol/L).
participants were given lifestyle interventions and randomly assigned 1:1 to receive intramuscular injections of testosterone (1000 mg) or placebo.
after two years of treatment, 87 (21%) of the 413 subjects in the placebo group developed diabetes, while only 55 (12%) of the 443 subjects in the testosterone group developed diabetes.
groups lost an average of 3 to 4 kg of weight.
results were followed up 2 years later, the placebo group had 87/413 (21%) and 55/443 (12%) participants with 2-h OGTT at 11-1 mmol/L or higher (relative risk 0.59).
, the average change in placebo group 2-h OGTT was -0.95 mmol/L and the testosterone group was -1.70 mmol/L compared to the baseline.
, the therapeutic effect was independent of baseline serum testosterone.
In addition, compared to the placebo group, patients who took testosterone after two years had lower peretone blood sugar, significantly reduced body fat, increased skeletal muscle mass and grip strength, and no difference in quality of life.
results suggest that testosterone has some additional benefits for preventing or reversing newly diagnosed T2DM, in addition to achieving moderate weight loss through healthy eating and increased activity.
Of course, given that men at risk of T2DM are often overweight or at risk of other chronic diseases, the researchers note that weight loss through a healthy lifestyle remains the primary measure.
: Wittert G, et al. Testosterone treatment to prevent or revert type 2 diabetes in men enrolled in a lifestyle programme (T4DM): a randomised, double-blind, placebo-controlled, 2-year, phase 3b trial. Lancet Diabetes Endocrinol. 2021 Jan; 9(1):32-45. doi: 10.1016/S2213-8587 (20) 30367-3. MedSci Original Source: MedSci Original Copyright Notice: All noted on this website "Source: The text, images and audio and video materials of Metz Medicine or Source: MedSci Originals are owned by Metz Medicine and may not be reproduced by any media, website or individual without authorization, and shall be reproduced with the words "Source: Mets Medicine".
all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
at the same time reproduced content does not represent the position of this site.
leave a message here